• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性胸膜间皮瘤的生存和预后因素:日本西部 314 例患者的回顾性研究。

Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.

机构信息

Department of Pharmacoepidemiology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

出版信息

Jpn J Clin Oncol. 2011 Jan;41(1):32-9. doi: 10.1093/jjco/hyq159. Epub 2010 Aug 26.

DOI:10.1093/jjco/hyq159
PMID:20798232
Abstract

OBJECTIVE

The objective in our study was to examine baseline and other characteristics associated with survival in patients with malignant pleural mesothelioma in Japan.

METHODS

Three hundred and fourteen patients with an adjudicated diagnosis of mesothelioma were examined. Survival was evaluated by the Kaplan-Meier method with the log-rank test. The Cox model was used to estimate the hazard ratio for the possible prognostic factors.

RESULTS

Of 314 patients, 223 (71%) died and only 40 (13%) were still alive at the end of the observation period starting from the day of diagnosis, while 51 (16%) were transferred to other hospitals or had the last health service contact before the end of the study period yielding the median survival of 308 days. In the multivariate analysis, age older than 70 years (hazard ratio = 2.17; 95% confidence interval, 1.36-3.46), non-epithelioid type (hazard ratio = 1.58; 95% confidence interval, 1.15-2.18), poor performance status (hazard ratio = 3.22; 95% confidence interval, 1.19-8.74), high white blood cell count (hazard ratio = 1.49; 95% confidence interval, 0.99-2.26) and high C-reactive protein level (hazard ratio = 1.80; 95% confidence interval, 1.06-3.06) were negatively associated with survival, after adjustment for other factors.

CONCLUSIONS

Some baseline conditions including old age, poor performance status, non-epithelioid type, high white blood cell count and high C-reactive protein level were determinants of poor survival of patients with malignant mesothelioma.

摘要

目的

本研究旨在探讨日本恶性胸膜间皮瘤患者的生存与基线和其他特征的关系。

方法

对 314 例经裁决诊断为间皮瘤的患者进行了检查。采用 Kaplan-Meier 法和对数秩检验评估生存情况。Cox 模型用于估计可能的预后因素的风险比。

结果

在 314 例患者中,223 例(71%)死亡,仅 40 例(13%)在诊断之日起的观察期结束时仍然存活,而 51 例(16%)转至其他医院或在研究结束前最后一次获得健康服务接触,中位生存时间为 308 天。在多变量分析中,年龄大于 70 岁(风险比=2.17;95%置信区间,1.36-3.46)、非上皮样类型(风险比=1.58;95%置信区间,1.15-2.18)、较差的表现状态(风险比=3.22;95%置信区间,1.19-8.74)、高白细胞计数(风险比=1.49;95%置信区间,0.99-2.26)和高 C 反应蛋白水平(风险比=1.80;95%置信区间,1.06-3.06)与生存呈负相关,调整其他因素后。

结论

一些基线情况,包括年龄较大、表现状态较差、非上皮样类型、高白细胞计数和高 C 反应蛋白水平,是恶性间皮瘤患者生存不良的决定因素。

相似文献

1
Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.恶性胸膜间皮瘤的生存和预后因素:日本西部 314 例患者的回顾性研究。
Jpn J Clin Oncol. 2011 Jan;41(1):32-9. doi: 10.1093/jjco/hyq159. Epub 2010 Aug 26.
2
Prognostic factors for 100 patients with malignant pleural mesothelioma.100例恶性胸膜间皮瘤患者的预后因素
Arch Environ Occup Health. 2010 Apr-Jun;65(2):65-9. doi: 10.1080/19338240903390271.
3
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.手术诊断和/或胸膜固定术后胸膜间皮瘤的结果和预后因素。
J Thorac Cardiovasc Surg. 2013 May;145(5):1305-11. doi: 10.1016/j.jtcvs.2012.09.023. Epub 2012 Oct 13.
4
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.胸膜外肺切除术与胸膜剥脱术/纤维板剥脱术治疗恶性胸膜间皮瘤的手术疗效:663例患者的结果
J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3. doi: 10.1016/j.jtcvs.2007.10.054. Epub 2008 Feb 14.
5
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.恶性胸膜间皮瘤:394例连续病例的临床病理及生存特征
Eur J Cardiothorac Surg. 2008 Feb;33(2):307-13. doi: 10.1016/j.ejcts.2007.09.044.
6
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.间皮瘤血清和胸腔积液中可溶性间皮素相关肽水平升高。
Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272. doi: 10.1016/j.athoracsur.2007.07.042.
7
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.恶性胸膜间皮瘤预后因素的验证:新南威尔士尘埃疾病委员会寻求赔偿的患者数据的回顾性分析。
Clin Lung Cancer. 2013 Jan;14(1):70-7. doi: 10.1016/j.cllc.2012.03.011. Epub 2012 Jun 1.
8
Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.恶性胸膜间皮瘤。113例患者预后因素的多变量分析。
Anticancer Res. 1993 May-Jun;13(3):683-9.
9
Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma.恶性胸膜间皮瘤行胸膜外肺切除术后主要并发症的危险因素。
Ann Thorac Surg. 2008 Apr;85(4):1206-10. doi: 10.1016/j.athoracsur.2007.11.065.
10
Prognostic factors and survival in malignant pleural mesothelioma.恶性胸膜间皮瘤的预后因素与生存情况
Eur Respir J. 1994 Jun;7(6):1035-8.

引用本文的文献

1
The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma.间皮瘤全身炎症评分与总生存期独立相关,并可预测胸膜间皮瘤多模式治疗的获益情况。
Cancers (Basel). 2025 Apr 20;17(8):1371. doi: 10.3390/cancers17081371.
2
The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis.全身炎症和临床病理特征对恶性胸膜间皮瘤生存的影响:一项多中心分析
Medicina (Kaunas). 2025 Jan 16;61(1):144. doi: 10.3390/medicina61010144.
3
Occupational and Environmental Asbestos Exposure and Survival of Patients with Asbestos-Related Cancer: A Follow-Up Study on Patients with Malignant Mesothelioma and Asbestos-Related Lung Cancer in Korea.
职业性和环境性石棉暴露与石棉相关癌症患者的生存情况:韩国恶性间皮瘤和石棉相关肺癌患者的随访研究
Toxics. 2023 Dec 25;12(1):20. doi: 10.3390/toxics12010020.
4
Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort.在研究中反映间皮瘤真实世界患者情况:来自ASSESS-meso队列的基线特征中期报告。
ERJ Open Res. 2023 Dec 27;9(6). doi: 10.1183/23120541.00467-2023. eCollection 2023 Nov.
5
Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study.纳武利尤单抗治疗日本恶性胸膜间皮瘤患者的临床疗效与安全性:MERIT研究的3年结果
JTO Clin Res Rep. 2020 Dec 29;2(3):100135. doi: 10.1016/j.jtocrr.2020.100135. eCollection 2021 Mar.
6
Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的流行病学与临床特征
Cancers (Basel). 2021 Aug 20;13(16):4194. doi: 10.3390/cancers13164194.
7
Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation.恶性胸膜间皮瘤的生物标志物——关于炎症的新观点
Cancers (Basel). 2021 Feb 6;13(4):658. doi: 10.3390/cancers13040658.
8
Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics.利用常规临床和实验室特征预测恶性胸膜间皮瘤的生存情况。
BMJ Open Respir Res. 2021 Jan;8(1). doi: 10.1136/bmjresp-2019-000506.
9
miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma.miR-182和miR-183通过靶向间皮瘤中的FOXO1促进细胞增殖和侵袭。
Front Oncol. 2018 Oct 22;8:446. doi: 10.3389/fonc.2018.00446. eCollection 2018.
10
Metastatic biphasic pleural mesothelioma presenting with cauda equina syndrome.以马尾综合征为表现的转移性双相性胸膜间皮瘤。
Radiol Case Rep. 2018 May 18;13(3):736-739. doi: 10.1016/j.radcr.2018.03.013. eCollection 2018 Jun.